Breaking NewsUK Cannabis Firm GW Pharmaceuticals Honoured By Her Majesty...

UK Cannabis Firm GW Pharmaceuticals Honoured By Her Majesty For Its Innovation


LEADING UK cannabis company GW Pharmaceuticals has received the Queen’s Award for Enterprise 2021 in recognition of its ground-breaking work in creating the world’s first regulatory approved, prescription cannabis-based medicines.

Regarded as the highest official UK award for British business, the Queen’s Award for Enterprise is an annual award which recognises outstanding achievement in Innovation and is now in its 55th year. 

Formed in 1998, GW has successfully navigated significant barriers to enable the development, manufacture and commercialisation of regulatory approved cannabis-based medicines such a Sativex and Epidiolex, supporting tens of thousands of patients and families around the world. 

Supporting Patients

Most of its 1,100 staff are employed in the UK and over the years has invested over £1.3bn in the research, development and infrastructure needed to bring innovative medicines to patients. 

Dr Geoffrey Guy, Founder and Chairman said: “We are honoured to receive such a prestigious award for British businesses. When Dr Brian Whittle and I founded GW 23 years ago, our mission was to improve the lives of seriously ill patients by unlocking the potential of the cannabis plant through rigorous scientific investigations and extensive clinical trials in order to obtain regulatory approval for such medicines to benefit patients. 

“Today, I want to thank every employee, clinician, researcher, patient and caregiver for helping advance and achieve that mission.”

Earlier this year Irish firm Jazz Pharmaceuticals had a $7.2bn takeover bid for NASDAQ-listed GW accepted.

Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.


Comments are closed.

Latest news

European Cannabis Stocks Review: SEED Innovations Shares Spike 25%, Futura Medical Signs Commercialisation Deal, & More From Akanda

AS quarterly and full-year results continued to be published across the global cannabis industry, European stocks enjoyed a relatively...

Creso Pharma Secures Heads of Agreement With Tattoo Aftercare Company Dr Pickles

Creso Pharma Limited (ASX:CPH, OTC:COPHF, FRA:1X8) (‘Creso Pharma’ or ‘the Company’) is pleased to advise it has signed anon-binding,...

LYPHE Group Poised For European Expansion As It ‘Steps Into Venture Capital’ With £5m Fundraise Led By Leafy Tunnel

LYPHE Group has announced the successful closure of its latest funding round, securing £5m in capital to fund expansion...

ACMD Reveals It Hasn’t Examined Cannabis Evidence For 14 Years As Signs Of UK’s ‘Appetite For Reform’ Grows

LAST week saw the British Government reinstate its hardline position on drug policy, as Policing Minister Kit Malthouse announced...

European Cannabis Industry ‘Potentially An Even Bigger Opportunity’ Than The US, And Investors Should ‘Wake Up To The Opportunities In Their Own Backyard’

NORTH American investment in the European cannabis industry has grown at pace over the last few years, with hundreds...

Major Cannabis Supplier Faces No Prison Sentence After Direct Support From Cancard, And After Hundreds Of Cancer Patients Come Forward To Say That He...

As reported by Cancard Cancard reports that one of their card holders and well known cannabis experts, Andrew Baines, will...

Must read

You might also likeRELATED
Recommended to you